- Home
- INSM vs CLS Comparison
INSM vs CLS Comparison
Compare INSM & CLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- CLS
- Stock Information
- Founded
- INSM 1988
- CLS 1994
- Country
- INSM United States
- CLS Canada
- Employees
- INSM N/A
- CLS N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- CLS Electrical Products
- Sector
- INSM Health Care
- CLS Technology
- Exchange
- INSM Nasdaq
- CLS Nasdaq
- Market Cap
- INSM 26.0B
- CLS 9.7B
- IPO Year
- INSM 2000
- CLS 1998
- Fundamental
- Price
- INSM $145.86
- CLS $252.03
- Analyst Decision
- INSM Strong Buy
- CLS Strong Buy
- Analyst Count
- INSM 18
- CLS 10
- Target Price
- INSM $146.81
- CLS $190.70
- AVG Volume (30 Days)
- INSM 2.0M
- CLS 3.2M
- Earning Date
- INSM 10-30-2025
- CLS 10-27-2025
- Dividend Yield
- INSM N/A
- CLS N/A
- EPS Growth
- INSM N/A
- CLS 55.91
- EPS
- INSM N/A
- CLS 4.59
- Revenue
- INSM $398,105,000.00
- CLS $10,587,200,000.00
- Revenue This Year
- INSM $31.95
- CLS $20.66
- Revenue Next Year
- INSM $125.46
- CLS $17.22
- P/E Ratio
- INSM N/A
- CLS $54.91
- Revenue Growth
- INSM 21.15
- CLS 20.52
- 52 Week Low
- INSM $60.40
- CLS $46.66
- 52 Week High
- INSM $149.08
- CLS $258.16
- Technical
- Relative Strength Index (RSI)
- INSM 72.40
- CLS 67.43
- Support Level
- INSM $138.73
- CLS $239.80
- Resistance Level
- INSM $148.22
- CLS $258.16
- Average True Range (ATR)
- INSM 3.85
- CLS 12.95
- MACD
- INSM -0.97
- CLS 1.49
- Stochastic Oscillator
- INSM 78.08
- CLS 91.77
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About CLS Celestica Inc.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.